Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. “The Hearth” is Forge’s home of a custom-designed cGMP facility dedicated to AAV manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
Oculogenex has developed a disruptive gene therapy technology that will provide a solution for the currently untreatable leading cause of vision impairment in the industrialized nations: advanced dry macular degeneration. Our transformative technology improves visual function, prevents photoreceptor death, and boosts antioxidant defenses. With a durable cost-effective therapy, Oculogenex has a $2.7 Trillion global market potential. Our product will prevent disability, depression, and improve the quality of life for hundreds of millions of people worldwide.